Focused On-demand Library for Patatin-like phospholipase domain-containing protein 5

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q7Z6Z6

UPID:

PLPL5_HUMAN

Alternative names:

GS2-like protein

Alternative UPACC:

Q7Z6Z6; B1AHL8; B3KPR1; Q6ZST0

Background:

Patatin-like phospholipase domain-containing protein 5, also known as GS2-like protein, is characterized by its significant triacylglycerol lipase activity. This enzyme plays a crucial role in lipid metabolism, breaking down triacylglycerols into fatty acids and glycerol, essential processes for energy production and lipid homeostasis in cells.

Therapeutic significance:

Understanding the role of Patatin-like phospholipase domain-containing protein 5 could open doors to potential therapeutic strategies. Its pivotal function in lipid metabolism suggests its involvement in metabolic disorders, offering a promising target for drug discovery aimed at treating lipid-related diseases.